Clinical Trials
14 trialsNCT05028166 2026-05-08
Individual Patient Compassionate Use of Mirdametinib
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Available
NCT05511714 2026-04-24
Expanded Access [11C] Methionine PET Imaging
St. Jude Children's Research Hospital
Available
NCT01163383 2026-04-13
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Children's Hospital of Philadelphia
Available
NCT07497984 2026-03-27
ITM11 Expanded Access Program
ITM Solucin GmbH
Available
NCT06404034 2026-03-04
Expanded Access to Gallium Maltolate (GaM)
Imaging Biometrics, LLC
No longer available
NCT03581240 2026-02-20
An Intermediate Expanded Use Trial of DFMO
Milton S. Hershey Medical Center
Available
NCT04566393 2026-01-28
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT07223606 2025-11-03
Fecal Microbiota Transplant for Neuroblastoma in a Single Patient
ProgenaBiome
No longer available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT04802447 2025-09-16
EAP
Roswell Park Cancer Institute
No longer available
NCT04617002 2025-08-20
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Jazz Pharmaceuticals
Approved for marketing
NCT05064306 2025-08-01
131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults
Memorial Sloan Kettering Cancer Center
No longer available
NCT06872489 2025-07-23
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
Second Life Therapeutics
Available
NCT01370330 2025-07-22
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
University of California, San Francisco
Available